Rhythm Pharmaceuticals (RYTM) Stock
Rare genetic obesity biotech with approved therapy. Here's the price, business snapshot, and what's worth knowing about Rhythm Pharmaceuticals in October 2026.
Rhythm Pharmaceuticals (RYTM) is a clinical-stage biopharmaceutical company focused on targeted treatments for rare genetic forms of obesity. Its lead therapy, setmelanotide (marketed as IMCIVREE), acts on the melanocortin-4 receptor pathway and has regulatory approvals for certain genetically defined obesity disorders. Rhythm’s model combines product sales, potential licensing and partnerships, and continued R&D to extend indications. Investors should be aware the company serves small, well-defined patient populations, so growth depends on diagnosis rates, reimbursement decisions and successful trial programmes. The business carries typical biotech risks — clinical and regulatory outcomes, competition from broader obesity drugs, manufacturing scale-up and commercial execution — which can create share-price volatility. With a market capitalisation around $7.12bn, Rhythm may interest investors seeking exposure to specialty therapeutics, but it best suits those comfortable with clinical-stage risk. This is general educational information, not personal financial advice; consider your circumstances and seek independent guidance before investing.
Rhythm Pharmaceuticals (RYTM) Stock Forecast
Analyst price target, next 12 months
$107.96
+16.3% vs today's $92.83
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Rhythm Pharmaceuticals have a consensus 12-month target of $107.96, above the current price of $92.83.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Rhythm Pharmaceuticals stock, expecting its value to rise significantly.
Financial Health
Rhythm Pharmaceuticals generates solid revenue and cash flow, with a strong profit margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Targeted obesity therapy
Setmelanotide addresses specific genetic pathways, offering predictable responses in defined patients — though growth depends on diagnosis and reimbursement.
Commercial scale-up
Expanding access and partnerships could lift revenues, but scaling manufacturing and securing payor support are crucial and can be challenging.
Clinical pipeline focus
Ongoing trials and label expansion present upside potential, while trial outcomes and regulatory reviews introduce uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
